.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

URINE EXAMINATION, ROUTINE; URINE, R/E
(Automated Strip test, Chemical, Light microscopy)

Physical

Colour Slight Lemon Yellow Pale yellow

Specific Gravity 1.020 1.001 - 1.030

pH 5.5 5.0 - 8.0

Chemical

Proteins Negative Negative

Glucose Negative Negative

Ketones Negative Negative

Bilirubin Negative Negative

Urobilinogen Negative Negative

Leucocyte Esterase Positive Negative

Nitrite Negative Negative

Microscopy

R.B.C. Negative 0.0 - 2.0 RBC/hpf

Pus Cells 5-7 WBC/HPF 0-5 WBC / hpf

Epithelial Cells 0-1 Epi Cells/hpf 0.0 - 5.0 Epi

cells/hpf
Casts None seen None seen/Lpf

Crystals None seen None seen

Others None seen None seen

Result Rechecked,
Please Correlate Clinically.

PatientReportSCSuperPanel.URINE_EXAMINATION_SC (Version: 6)

Page 1 of 10

*298504375*
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.

PatientReportSCSuperPanel.URINE_EXAMINATION_SC (Version: 6)

Page 2 of 10

*298504375*
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

HbA1c (GLYCOSYLATED HEMOGLOBIN), BLOOD
(HPLC)

HbA1c 5.2 %
Estimated average glucose (eAG) 103 mg/dL

Interpretation
-------------------------------------------------------------------------------
| As per American Diabetes Association (ADA) |
|-------------------------------------------------------------------------------|
| Reference Group | HbA1c in % |
|-------------------------------|-----------------------------------------------|
| Non diabetic adults >=18 years| 4.0 - 5.6 |
|-------------------------------|-----------------------------------------------|
| At risk (Prediabetes) | 5.7 - 6.4 |
|-------------------------------|-----------------------------------------------|
| Diagnosing Diabetes | >= 6.5 |
|-------------------------------|-----------------------------------------------|
| Therapeutic goals for glycemic| < 7.0 |
| control | |
-------------------------------------------------------------------------------

Note
1. Since HbA1c reflects long term fluctuations in the blood glucose concentration, a diabetic patient who
is recently under good control may still have a high concentration of HbA1c. Converse is true for a
diabetic previously under good control but now poorly controlled
2. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life
expectancy and no significant cardiovascular disease. In patients with significant complications of
diabetes, limited life expectancy or extensive co-morbid conditions, targeting a goal of < 7.0 % may not
be appropriate
3. Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered,
particularly when the A1C result does not correlate with the patient’s blood glucose levels
4. In patients with HbA1c level between 7-8%, Glycemark (1,5 Anhydroglucitol) test may be done to
identify those with more frequent and extreme hyperglycemic excursions

Comments
HbA1C reflects average glycemia over approximately 3 months, the test is the major tool for assessing
glycemic control and has strong predictive value for diabetes complications. Thus, HbA1C testing should be
performed routinely in all patients with diabetes - at initial assessment and as part of continuing care.

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*298504375*
Page 3 of 10
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

Measurement approximately every 3 months determines whether patients’ glycemic targets have been
reached and maintained. The frequency of A1C testing should depend on the clinical situation, the treatment
regimen, and the clinician’s judgement.

ADA Recommendations for HbA1c testing

1. Perform the A1C test at least two times a year in patients who are meeting treatment goals (and who
have stable glycemic control)
2. Perform the A1C test quarterly in patients whose therapy has changed or who are not meeting
glycemic goals

Factors that Interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF)
and chemically modified derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can
affect the accuracy of HbA1c measurements

Factors that affect interpretation of HbA1c Results: Any condition that shortens erythrocyte survival or
decreases mean erythrocyte age (e.g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and
HbSC) will falsely lower HbA1c test results regardless of the assay method used. Iron deficiency anemia is
associated with higher HbA1c

PatientReportSCSuperPanel.HBELECTRO_SC (Version: 7)

*298504375*
Page 4 of 10
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

HEMOGRAM
(Electrical Impedence & Flow,Capillary photometry)

Hemoglobin 12.10 g/dL 11.50 - 15.00

Packed Cell Volume (PCV) 34.60 % 36.00 - 46.00

RBC Count 3.78 mill/mm3 3.80 - 4.80

MCV 91.50 fL 80.00 - 100.00

MCH 32.00 pg 27.00 - 32.00

MCHC 35.00 g/dL 32.00 - 35.00

Red Cell Distribution Width (RDW) 14.20 % 11.50 - 14.50

Total Leukocyte Count (TLC) 6.17 thou/mm3 4.00 - 10.00

Differential Leucocyte Count (DLC)

Segmented Neutrophils 52.80 % 40.00 - 80.00

Lymphocytes 36.60 % 20.00 - 40.00
Monocytes 9.10 % 2.00 - 10.00
Eosinophils 1.50 % 1.00 - 6.00
Basophils 0.00 % <2.00
Absolute Leucocyte Count

Neutrophils 3.26 thou/mm3 2.00 - 7.00

Lymphocytes 2.26 thou/mm3 1.00 - 3.00
Monocytes 0.56 thou/mm3 0.20 - 1.00
Eosinophils 0.09 thou/mm3 0.02 - 0.50
Basophils 0.00 thou/mm3 0.01 - 0.10
Platelet Count 172.0 thou/mm3 150.00 - 450.00

*298504375*
Page 5 of 10
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

Mean Platelet Volume (MPV) 13.90 fL 6.50 - 12.00

ESR 5 mm/hr 0.00 - 20.00

Note
1. As per the recommendation of International council for Standardization in Hematology, the differential
leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of
blood

2. Test conducted on EDTA whole blood

*298504375*
Page 6 of 10
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

CORTISOL, MORNING, SERUM @ 9.82 µg/dL 4.30 - 22.40
(CLIA)

Note: Cortisol is best measured in the morning when evaluating for possible Adrenal Insufficiency and
best measured in the afternoon or evening to differentiate normal and Cushings Syndrome subjects.
Diurnal rhythmicity of cortisol is increased by systemic disease and stress.

Clinical Use
* Direct assessment of Adrenal function

Increased levels: Cushings Syndrome, Ectopic ACTH syndrome, Ectopic CRH syndrome, Adrenal
adenoma / carcinoma, Adrenal micronodular dysplasia, Adrenal macronodular
hyperplasia, Stress
Decreased Levels - Addisons disease, Pituitary dysfunction

CALCIUM, SERUM 9.10 mg/dL 8.80 - 10.60

(Arsenazo III)

PHOSPHORUS, SERUM 3.70 mg/dL 2.40 - 4.40

(Phosphomolybdate)

PTH (PARATHYROID HORMONE) INTACT, SERUM 48.80 pg/mL 14.00 - 72.00

@
(CLIA)
Notes
1. Test results should be interpreted in conjunction with serum calcium and phosphorus levels, and
clinical findings.
2. Elevated PTH with normal serum calcium levels may be indicative of Secondary causes of
hyperparathyroidism like vitamin D deficiency. It may not always be indicative of Primary
hyperparathyroidism.
3. PTH is secreted in a pulsatile manner with an overall circadian rhythm characterized by a nocturnal
rise.

Clinical Use
· Diagnose hyperparathyroidism

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*298504375*
Page 7 of 10
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

· Monitor severity of secondary hyperparathyroidism in chronic renal failure
· Discriminate primary hyperparathyroidism from tumor hypercalcemia

Increased Levels
· Primary hyperparathyroidism
· Secondary hyperparathyroidism
· Renal failure
· Pseudohypoparathyroidism

Decreased Levels
· Hypoparathyroidism
· Hypercalcemia of malignancy

VITAMIN D, 25 - HYDROXY, SERUM 40.83 nmol/L

(Chemiluminescence)

Interpretation
-------------------------------------------------------------
| LEVEL | REFERENCE RANGE | COMMENTS |
| | IN nmol/L | |
|---------------|-----------------|---------------------------|
| Deficient | < 50 | High risk for developing |
| | | bone disease |
|---------------|-----------------|---------------------------|
| Insufficient | 50-74 | Vitamin D concentration |
| | | which normalizes |
| | | Parathyroid hormone |
| | | concentration |
|---------------|-----------------|---------------------------|
| Sufficient | 75-250 | Optimal concentration |
| | | for maximal health benefit|
|---------------|-----------------|---------------------------|
| Potential | >250 | High risk for toxic |
| intoxication | | effects |
-------------------------------------------------------------

Note
· The assay measures both D2 (Ergocalciferol) and D3 (Cholecalciferol) metabolites of vitamin D.
· 25 (OH)D is influenced by sunlight, latitude, skin pigmentation, sunscreen use and hepatic function.
· Optimal calcium absorption requires vitamin D 25 (OH) levels exceeding 75 nmol/L.
PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*298504375*
Page 8 of 10
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

· It shows seasonal variation, with values being 40-50% lower in winter than in summer.
· Levels vary with age and are increased in pregnancy.
· A new test Vitamin D, Ultrasensitive by LC-MS/MS is also available

Comments
Vitamin D promotes absorption of calcium and phosphorus and mineralization of bones and teeth. Deficiency
in children causes Rickets and in adults leads to Osteomalacia. It can also lead to Hypocalcemia and
Tetany. Vitamin D status is best determined by measurement of 25 hydroxy vitamin D, as it is the major
circulating form and has longer half life (2-3 weeks) than 1,25 Dihydroxy vitamin D (5-8 hrs).

Decreased Levels
· Inadequate exposure to sunlight
· Dietary deficiency
· Vitamin D malabsorption
· Severe Hepatocellular disease
· Drugs like Anticonvulsants
· Nephrotic syndrome

Increased levels
Vitamin D intoxication

PatientReportSCSuperPanel.SP_GENERAL_TEMPLATE01_SC (Version: 7)

*298504375*
Page 9 of 10
.

S60 - MORVINANDAN DIAGNOSTIC CENTRE

LLP

Name : Ms. SARAH ZIA Collected : 28/11/2020 9:30:00AM

Received : 28/11/2020 9:46:37AM
Lab No. : 298504375 Age: 25 Years Gender: Female Reported : 30/11/2020 4:19:11PM
A/c Status : P Ref By : Dr.ARUN DEWAN Report Status : Final

Test Name Results Units Bio. Ref. Interval

CULTURE, URINE @
(Conventional culture, Automated Identification & Sensitivity)
Type of Specimen :

Result :- No Aerobic pyogenic organism grown

Dr Himangshu Mazumdar Dr.Kamal Modi Dr Nimmi Kansal Dr Ritu Nayar

MD, Biochemistry MD, Biochemistry MD, Biochemistry MD, Microbiology
Senior Consultant - Clinical Chemistry Consultant Biochemist National Head - Clinical Chemistry & Deputy HOD - Microbiology & Serology
& Biochemical Genetics NRL - Dr Lal PathLabs Ltd Biochemical Genetics NRL - Dr Lal PathLabs Ltd
NRL - Dr Lal PathLabs Ltd NRL - Dr Lal PathLabs Ltd

Dr Parul Joshi Dr Shalabh Malik

MD, Pathology MD, Microbiology
Chief of Laboratory National Head - Microbiology &
Dr Lal PathLabs Ltd Serology
NRL - Dr Lal PathLabs Ltd

-------------------------------End of report --------------------------------

IMPORTANT INSTRUCTIONS

*Test results released pertain to the specimen submitted .*All test results are dependent on the quality of the sample received by the Laboratory .
*Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should be clinically correlated by the Referring Physician .*Sample
repeats are accepted on request of Referring Physician within 7 days post reporting.*Report delivery may be delayed due to unforeseen
circumstances. Inconvenience is regretted.*Certain tests may require further testing at additional cost for derivation of exact value. Kindly submit
request within 72 hours post reporting.*Test results may show interlaboratory variations .*The Courts/Forum at Delhi shall have exclusive
jurisdiction in all disputes/claims concerning the test(s) & or results of test(s).*Test results are not valid for medico legal purposes. * Contact
customer care Tel No. +91-11-39885050 for all queries related to test results.
(#) Sample drawn from outside source.

PatientReportCategory.MICRO_AEROBIC (Version: 6)

*298504375* Page 10 of 10